Previous Close | 0.1850 |
Open | 0.1850 |
Bid | 0.2055 x 0 |
Ask | 0.1930 x 0 |
Day's Range | 0.1850 - 0.2050 |
52 Week Range | 0.1006 - 0.9400 |
Volume | |
Avg. Volume | 194,458 |
Market Cap | 23.646M |
Beta (5Y Monthly) | 1.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5260 |
Earnings Date | May 05, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ADXN.SW
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guidance. “We ended 2022 with CHF7.0 million of cash and expect to be able to finance our operations until Q3 2023. We continue to focus on entering into collaborative arra
Addex to receive USD 1 million in additional research fundingCollaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 8, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the research term of its collaboration agreement with Indivior PLC (LON: INDV) for the discovery of novel o
CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its Q3 financial results for the period ended September 30, 2022 and provided a corporate upd